Dion MJ - Search Results

1

Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: a randomized trial.

Menzies D, Long R, Trajman A, Dion MJ, Yang J, Al Jahdali H, Memish Z, Khan K, Gardam M, Hoeppner V, Benedetti A, Schwartzman K. Menzies D, et al. Among authors: dion mj. Ann Intern Med. 2008 Nov 18;149(10):689-97. doi: 10.7326/0003-4819-149-10-200811180-00003. Ann Intern Med. 2008. PMID: 19017587 Clinical Trial.

2

Treatment completion and costs of a randomized trial of rifampin for 4 months versus isoniazid for 9 months.

Menzies D, Dion MJ, Rabinovitch B, Mannix S, Brassard P, Schwartzman K. Menzies D, et al. Among authors: dion mj. Am J Respir Crit Care Med. 2004 Aug 15;170(4):445-9. doi: 10.1164/rccm.200404-478OC. Epub 2004 Jun 1. Am J Respir Crit Care Med. 2004. PMID: 15172892 Clinical Trial.

3

Impact of treatment completion, intolerance and adverse events on health system costs in a randomised trial of 4 months rifampin or 9 months isoniazid for latent TB.

Aspler A, Long R, Trajman A, Dion MJ, Khan K, Schwartzman K, Menzies D. Aspler A, et al. Among authors: dion mj. Thorax. 2010 Jul;65(7):582-7. doi: 10.1136/thx.2009.125054. Thorax. 2010. PMID: 20627913 Clinical Trial.

4

Four Months of Rifampin or Nine Months of Isoniazid for Latent Tuberculosis in Adults.

Menzies D, Adjobimey M, Ruslami R, Trajman A, Sow O, Kim H, Obeng Baah J, Marks GB, Long R, Hoeppner V, Elwood K, Al-Jahdali H, Gninafon M, Apriani L, Koesoemadinata RC, Kritski A, Rolla V, Bah B, Camara A, Boakye I, Cook VJ, Goldberg H, Valiquette C, Hornby K, Dion MJ, Li PZ, Hill PC, Schwartzman K, Benedetti A. Menzies D, et al. Among authors: dion mj. N Engl J Med. 2018 Aug 2;379(5):440-453. doi: 10.1056/NEJMoa1714283. N Engl J Med. 2018. PMID: 30067931 Free article. Clinical Trial.

5

In closely monitored patients, adherence in the first month predicts completion of therapy for latent tuberculosis infection.

Menzies D, Dion MJ, Francis D, Parisien I, Rocher I, Mannix S, Schwartzman K. Menzies D, et al. Among authors: dion mj. Int J Tuberc Lung Dis. 2005 Dec;9(12):1343-8. Int J Tuberc Lung Dis. 2005. PMID: 16466056

6

Measurement of health preferences among patients with tuberculous infection and disease.

Dion MJ, Tousignant P, Bourbeau J, Menzies D, Schwartzman K. Dion MJ, et al. Med Decis Making. 2002 Sep-Oct;22(5 Suppl):S102-14. doi: 10.1177/027298902237706. Med Decis Making. 2002. PMID: 12369225

7

Feasibility and reliability of health-related quality of life measurements among tuberculosis patients.

Dion MJ, Tousignant P, Bourbeau J, Menzies D, Schwartzman K. Dion MJ, et al. Qual Life Res. 2004 Apr;13(3):653-65. doi: 10.1023/B:QURE.0000021320.89524.64. Qual Life Res. 2004. PMID: 15130028

8

Factors associated with treatment adherence in a randomised trial of latent tuberculosis infection treatment.

Trajman A, Long R, Zylberberg D, Dion MJ, Al-Otaibi B, Menzies D. Trajman A, et al. Among authors: dion mj. Int J Tuberc Lung Dis. 2010 May;14(5):551-9. Int J Tuberc Lung Dis. 2010. PMID: 20392347 Clinical Trial.

9

Respiratory day hospital: a novel approach to acute respiratory care.

Schwartzman K, Duquette G, Zaoudé M, Dion MJ, Lagacé MA, Poitras J, Cosio MG. Schwartzman K, et al. Among authors: dion mj. CMAJ. 2001 Oct 16;165(8):1067-71. CMAJ. 2001. PMID: 11699705 Free PMC article.

10

Profiles of neurological outcome prediction among intensivists.

Racine E, Dion MJ, Wijman CA, Illes J, Lansberg MG. Racine E, et al. Among authors: dion mj. Neurocrit Care. 2009 Dec;11(3):345-52. doi: 10.1007/s12028-009-9225-9. Neurocrit Care. 2009. PMID: 19430929 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

11 results

Search Page